(iv) Durvalumab: Durvalumab is a human IgG1 κ monoclonal antibody specifically designed to target PD-L1.48 NCT01693562 was the first study on humans to test durvalumab in advanced lung cancer patients, initially including all patients but later focusing only on those with PD-L1 expression. The gene discussed is CD274; the disease is lung carcinoma.